Decreases in smoking during treatment for methamphetamine-use disorders: preliminary evidence

Behav Pharmacol. 2018 Jun;29(4):370-374. doi: 10.1097/FBP.0000000000000349.

Abstract

Despite high rates of smoking (70-90%) and the severely negative impact of smoking on physical and mental health, only 12% of individuals receiving stimulant-use disorder treatment also receive smoking-cessation treatment. The aim of this investigation was to examine the effect of a contingency management (CM) intervention targeting methamphetamine (MA) use on cigarette smoking. Sixty-one adults with MA-use disorders who were smokers were assigned to CM or standard psychosocial treatment. Rates of smoking-negative breath samples (carbon monoxide <3 ppm) were compared between the two groups while controlling for baseline carbon monoxide level, marijuana use, MA use, and time. This subgroup of mostly male (59%) participants included 44 participants in the CM group and 17 participants in the standard psychosocial treatment. Tobacco smoking participants who received CM targeting MA use were 140% (odds ratio: 2.395; 95% confidence interval: 1.073-5.346) more likely to submit a smoking-negative breath sample relative to standard psychosocial treatment during the treatment period, holding constant several other prespecified covariates. This study provides evidence that a behavioral treatment for MA use results in reductions in cigarette smoking in adults with MA-use disorder.

Publication types

  • Research Support, N.I.H., Extramural

MeSH terms

  • Adult
  • Behavior Therapy / methods
  • Cigarette Smoking / metabolism
  • Cigarette Smoking / psychology*
  • Cigarette Smoking / therapy
  • Female
  • Humans
  • Male
  • Methamphetamine / adverse effects
  • Middle Aged
  • Preliminary Data
  • Smoking / psychology
  • Smoking Cessation / methods*
  • Substance-Related Disorders / physiopathology
  • Substance-Related Disorders / psychology*
  • Tobacco Smoking
  • Tobacco Use Disorder

Substances

  • Methamphetamine